Back

P2Y12 pretreatment in NSTE-ACS is needed

26 August 2018 (15:06 - 15:18)
Organised by:
Congress Presentation Part of: Dual antiplatelet therapy and PCI - Important controversies Pharmacotherapy ESC Premium Access ESC Congress 2018

About the speaker

Photo
Professor Philippe Gabriel Steg

Hospital Bichat-Claude Bernard, Paris (France)

9 More presentations in this session

Presentation thumbnail
DAPT - Longer is better
Doctor J. Udell (Toronto, CA)
Slides Video
Presentation thumbnail
DAPT - Shorter is better
Professor M. Valgimigli (Lugano, CH)
Slides Video
Presentation thumbnail
DAPT - Longer is better - Rebuttal.
Doctor J. Udell (Toronto, CA)
Video
Presentation thumbnail
DAPT - Shorter is better - Rebuttal.
Professor M. Valgimigli (Lugano, CH)
Slides Video
Presentation thumbnail
DAPT - Chairperson conclusion.
Doctor H. Mardikar (Nagpur, IN)
Video

Access the full session

Session thumbnail
Dual antiplatelet therapy and PCI - Important controversies

The Event

Event poster

ESC Congress 2018

26 August 2018 15:06 CET
You may be interested in
thumbnail
Congress Presentation
The effect of P2Y12 inhibitor pretreatment vs. no pretreatment on major bleeding among patients with NSTE-ACS: an updated meta-analysis and meta-regression pooling 41,548 patients from 11 studies
27 August 2021
thumbnail
Webinar
Antithrombotic strategy for ACS: from default to alternative strategies. ESC 2023 Clinical Practice Guidelines - Webinar Series
28 November 2023
thumbnail
Congress Presentation
Antiplatelet therapy prescription patterns for acute coronary syndrome: a decade analysed
28 August 2020
thumbnail
Congress Presentation
Less bleeding by omitting aspirin in non-ST-segment elevation acute coronary syndrome patients (LEGACY)
1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources